Literature DB >> 21458881

Comparative assessment of the recognition of domain-specific CD163 monoclonal antibodies in human monocytes explains wide discrepancy in reported levels of cellular surface CD163 expression.

Maciej Bogdan Maniecki1, Anders Etzerodt, Søren Kragh Moestrup, Holger Jon Møller, Jonas Heilskov Graversen.   

Abstract

BACKGROUND: CD163 is expressed exclusively on cells of the monocyte/macrophage lineage and is widely used as a marker of human macrophages. Further, it has been suggested as a diagnostic marker of monocyte/macrophage activity in inflammatory conditions and as a therapeutic target. However, studies continue to exhibit great discrepancy in the measured percentage of CD163-expressing blood monocytes in healthy individuals. In this study we sought to clarify this inconsistency in reported levels of CD163 surface expression by a detailed analysis of a panel of CD163 antibodies used in previous studies.
MATERIALS AND METHODS: The cellular distribution of CD163 on human peripheral blood monocytes in freshly drawn blood and peripheral blood mononuclear cells isolated from buffy-coats was investigated by flow cytometry using CD163 monoclonal antibodies recognizing scavenger receptor cysteine-rich (SRCR) domain 1 (MAC2-158), domain 4 (R-20), domain 7 (GHI/61), and domain 9 (RM3/1). The CD163 monoclonal antibodies were characterized in binding and endocytosis experiments in human macrophages and CD163-transfected Flp-In CHO cells. Calcium-dependent ligand binding was assessed using surface plasmon resonance, and the specificity of the CD163 monoclonal antibodies was analyzed by western blotting. RESULTS AND DISCUSSION: Flow cytometric analysis revealed that the estimated proportion of CD163-expressing human peripheral blood monocytes increased when using CD163 monoclonal antibodies recognizing epitopes in the N-terminal part of CD163, remote from the membrane surface. Moreover, the proportion of CD163 positive monocytes observed was highly dependent on free calcium. GHI/61 did not exhibit CD163 binding in the presence of calcium as measured by surface plasmon resonance, which was in agreement with the concordant loss of binding in heparin-stabilized whole blood observed by flow cytometry. In contrast, RM3/1 exhibited weak binding to CD163 in the absence of calcium but high affinity binding to CD163 in the presence of calcium. R-20 and MAC2-158 were unaffected by extracellular calcium levels. The latter SRCR domain 1mAb consistently recognized more than 80% CD163-positive monocytes in human peripheral blood.
CONCLUSION: Epitope accessibility and extracellular calcium dependence elucidate discrepancies in reported levels of monocytic CD163 expression. Utilizing monoclonal antibodies to the N-terminal part of CD163 more than 80% monocytes in human peripheral blood could be identified as CD163 positive, indicating that most, and conceivably all, human peripheral blood monocytes do express CD163.
Copyright © 2011 Elsevier GmbH. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21458881     DOI: 10.1016/j.imbio.2011.02.001

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  14 in total

1.  Up-regulation of CD163 expression in subpopulations of blood monocytes after kidney allograft transplantation.

Authors:  L Čurnová; K Mezerová; V Švachová; M Fialová; M Novotný; E Čečrdlová; O Viklický; I Stříž
Journal:  Physiol Res       Date:  2020-09-09       Impact factor: 1.881

2.  Targeting the hemoglobin scavenger receptor CD163 in macrophages highly increases the anti-inflammatory potency of dexamethasone.

Authors:  Jonas H Graversen; Pia Svendsen; Frederik Dagnæs-Hansen; Jakob Dal; Gabriele Anton; Anders Etzerodt; Mikkel D Petersen; Peter A Christensen; Holger J Møller; Søren K Moestrup
Journal:  Mol Ther       Date:  2012-05-29       Impact factor: 11.454

3.  Differential expression of CD163 on monocyte subsets in healthy and HIV-1 infected individuals.

Authors:  Emma Tippett; Wan-Jung Cheng; Clare Westhorpe; Paul U Cameron; Bruce J Brew; Sharon R Lewin; Anthony Jaworowski; Suzanne M Crowe
Journal:  PLoS One       Date:  2011-05-20       Impact factor: 3.240

Review 4.  CD163 and inflammation: biological, diagnostic, and therapeutic aspects.

Authors:  Anders Etzerodt; Søren K Moestrup
Journal:  Antioxid Redox Signal       Date:  2012-10-19       Impact factor: 8.401

Review 5.  Identification and manipulation of tumor associated macrophages in human cancers.

Authors:  Moniek Heusinkveld; Sjoerd H van der Burg
Journal:  J Transl Med       Date:  2011-12-16       Impact factor: 5.531

Review 6.  Drug Trafficking into Macrophages via the Endocytotic Receptor CD163.

Authors:  Jonas Heilskov Graversen; Søren Kragh Moestrup
Journal:  Membranes (Basel)       Date:  2015-06-23

7.  Structural basis for inflammation-driven shedding of CD163 ectodomain and tumor necrosis factor-α in macrophages.

Authors:  Anders Etzerodt; Mie Rostved Rasmussen; Pia Svendsen; Athena Chalaris; Jeanette Schwarz; Ian Galea; Holger Jon Møller; Søren Kragh Moestrup
Journal:  J Biol Chem       Date:  2013-11-25       Impact factor: 5.157

8.  The identification of CD163 expressing phagocytic chondrocytes in joint cartilage and its novel scavenger role in cartilage degradation.

Authors:  Kai Jiao; Jing Zhang; Mian Zhang; Yuying Wei; Yaoping Wu; Zhong Ying Qiu; Jianjun He; Yunxin Cao; Jintao Hu; Han Zhu; Li-Na Niu; Xu Cao; Kun Yang; Mei-Qing Wang
Journal:  PLoS One       Date:  2013-01-11       Impact factor: 3.240

9.  CD14+CD16+ and CD14+CD163+ monocyte subpopulations in kidney allograft transplantation.

Authors:  Alena Sekerkova; Eva Krepsova; Eva Brabcova; Janka Slatinska; Ondrej Viklicky; Vera Lanska; Ilja Striz
Journal:  BMC Immunol       Date:  2014-02-06       Impact factor: 3.615

10.  The human tissue-biomaterial interface: a role for PPARγ-dependent glucocorticoid receptor activation in regulating the CD163+ M2 macrophage phenotype.

Authors:  Samuel J Bullers; Simon C Baker; Eileen Ingham; Jennifer Southgate
Journal:  Tissue Eng Part A       Date:  2014-05-20       Impact factor: 3.845

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.